Professor Michelle Williams is a Professor of Cardiovascular Imaging at the University of Edinburgh and Honorary Consultant Radiologist at NHS Lothian. She is Associate Director of the British Heart Foundation Data Science Centre and the Imaging theme lead. Her research centers around multi-modality non-invasive imaging of the heart and blood vessels, including using machine learning and other advanced analytic techniques. She is president of the British Society of Cardiovascular Imaging, member of the executive community of the European Society of Cardiovascular Radiology, member of the Board of Directors of the SCCT, and chair of the SCCT education committee.

Prof Ray is currently President of the European Atherosclerosis Society, Chair of the World Heart Federation Cholesterol Roadmap, National Lead for CVD NIHR Academic research Collaboration, Clinical Director for Research HDR UK Digital Innovation Hub DISCOVER Now, Director of ICTU-Global which is an academic ARO. He received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, his MD (2004) at the University of Sheffield, a postdoctoral fellowship at Harvard Medical School and finally an MPhil in epidemiology (2007) from the University of Cambridge. His research involves lipids, diabetes and population health serving as global lead for trials and registries. He has >160,000 citations and since 2018 has been recognised by Clarivate Analytics as among the top 0.1% of authors in global medicine. In 2023 he was inducted as a Fellow of the Academy of Medical Sciences, which is UK’s highest honour for clinician scientists.

Dr Mark Nidorf is affiliated with the Heart and Vascular Research Institute at the Perkins Research Institute in Perth Western Australia. His clinical research interest in atherosclerosis led him to initiate the LoDoCo trials of low dose colchicine for the secondary prevention of coronary disease.

Professor Anthony (Tony) Keech is Senior Principal Research Fellow and Senior Associate Director at NHMRC Clinical Trials Centre. Tony is Professor of Medicine, Cardiology and Epidemiology at the University of Sydney, an internationally known researcher in the field of cardiovascular clinical trials, and chair and principal investigator of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. His research has influenced health outcomes, particularly in treatments of acute myocardial infarction, cardiovascular disease prevention of chronic heart disease, and diabetes and its vascular complications. He is recognised internationally for collaborative research into coronary risk factors, treatments for acute coronary syndromes, prediction of vascular disease, and treatment and diabetes complication prevention. Most of Tony's research has consisted of large national and international projects undertaken in collaboration with many clinical research investigators and drug companies.

Clinical Professor Michaela Lucas is an Immunologist/Immunopathologist and Clinician-Scientist with conjoint appointments at Sir Charles Gairdner Hospital, PathWest, the Perth Children’s Hospital, and The University of Western Australia. She is the immediate past President of the Australasian Society of Immunology and Allergy and co-chair and director of the National Allergy Council (NAC). She is the Principal Investigator of the PERTH trial, investigating the impact of plastics and plastic associated chemicals on inflammation and metabolic disease.

Dr Louise Naylor is a researcher and academic in the University of Western Australia’s School of Human Sciences and also an ESSA Accredited Exercise Physiologist. She believes exercise is medicine and can be used to treat, prevent or reduce the impact of chronic disease. Her research explores how exercise training can contribute to rehabilitating and improving health outcomes in individuals with, or at risk of, cardiovascular disease, survivors of childhood cancer and children with metabolic conditions. After completing her undergraduate degree and PhD at UWA, Dr Naylor commenced her research career working with both elite athletes and chronically ill individuals with conditions such as heart failure and obesity. Her research investigates how exercise can improve health and wellbeing, quality of life, depression and anxiety. In a growing and research-led field, her projects have spanned topics such as understanding how to optimise prescriptions for survivors of cancer, patients with heart failure, ageing men, and patients with diabetes. Her research further investigates the need for exercise programs to be personalised to be effective, and the difference between different individual responses to exercise programs and why some people don't respond at all. Dr Naylor is also involved in basic science research to add further mechanistic insights into the regulation of the cardiovascular system and generate a multifaceted understanding of cardiac and vascular exercise physiology. As an ESSA Accredited Exercise Physiologist, Dr Naylor works as a Senior Exercise Physiologist in the Cardiac Rehabilitation Service at Fiona Stanley Hospital.

Dr. R. Preston Mason has been a member of the Cardiovascular Division at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, USA. Dr Mason is President and Founder of Elucida Research, a biotechnology research firm in Beverly, Massachusetts. He has received many awards for his research in cardiovascular pharmacology and teaching over the past 35 years. Prior to coming to Boston, he was on the faculties of the University of Connecticut School of Medicine and Drexel University School of Medicine as professor. Dr. Mason has served on a number of grant review committees for the National Institute of Health, American Heart Association and reviewer for a number of prestigious journals. He has authored or co-authored 200 full scientific articles, has multiple patents and receives frequent requests to speak at national and international conferences. He has published over 50 research articles and given more than 100 scientific presentations related specifically to his research on the role of omega-3 fatty acids in cardiovascular disease